CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups.
Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
PJ 代谢指纹反映了 PDAC 分子亚型和免疫微环境，证实 PJ 是用于个性化治疗的有前景的生物标志物来源。
代谢重编程是胰腺导管腺癌（PDAC）的标志性特征。据报道，胰液（PJ）代谢特征可预测PDAC的肿瘤学结局。将PJ谱分析与肿瘤微环境的转录组学和空间表征相结合，有助于识别具有特殊脆弱性的PDAC。
我们对26例PDAC样本进行了转录组分析，根据其PJ代谢特征分为3个代谢簇（M_CL）。我们分析了分子亚型和转录差异。通过在肿瘤切片上进行多维成像进行了验证。
胰液代谢谱与PDAC转录组分子亚型相关（p=0.004）。被鉴定为M_CL1的肿瘤表现出非鳞状分子表型，并显示出更长的生存期。富集分析显示，与预后较差的M_CL2组相比，M_CL1样本中免疫基因和通路上调，这一差异通过组织切片上的免疫荧光得到证实。通过xCell对39个免疫特征进行的富集分析证实，与M_CL1相比，M_CL2中免疫特征减少，并能够对与更长生存期相关的患者进行分层。
We performed a transcriptomic analysis of 26 PDAC samples grouped into 3 metabolic clusters (M_CL) according to their PJ metabolic profile. We analyzed molecular subtypes and transcriptional differences. Validation was performed by multidimensional imaging on tumor slides.
Pancreatic juice metabolic profiling was associated with PDAC transcriptomic molecular subtypes (p=0.004). Tumors identified as M_CL1 exhibited a non-squamous molecular phenotype and demonstrated longer survival. Enrichment analysis revealed the upregulation of immune genes and pathways in M_CL1 samples compared to M_CL2, the group with worse prognosis, a difference confirmed by immunofluorescence on tissue slides. Enrichment analysis of 39 immune signatures by xCell confirmed decreased immune signatures in M_CL2 compared to M_CL1 and allowed a stratification of patients associated with longer survival. DISCUSSION: PJ metabolic fingerprints reflect PDAC molecular subtypes and the immune microenvironment, confirming PJ as a promising source of biomarkers for personalized therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
